These inhibitors are intended to bind to the p53-binding pocket of MDM2, which prevents MDM2 from binding to p53, thus releasing p53 from MDM2-mediated inhibition and eliciting tumor suppression in a p53-dependent manner. Here, MDM2 is linked to neoplasm.